A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn


Contact us at to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).



Standigm applies cutting-edge AI technologies to drug discovery. AI and biology experts team up to build a real-world AI model for the pharmaceutical industry. We currently focus on predicting new indications for existing drugs, called drug repositioning through the deeply trained AI model with molecular features of drug responses and drug uses. Standigm generated tens of drug candidates for cancers, Parkinson’s disease (PD), autism, fatty liver diseases (NASH) and more. We promise practical benefits on time and cost in pharmaceutical industry by eliminating some of the uncertainty in the drug discovery process.

Year Founded
South Korea based
$3.69 M
Research Use Case
  • Target identification/validation
  • Lead Identification
  • Lead optimization
  • Drug Repurposing
Product type
  • small molecules

Industry Partnerships

2017CrystalGenomicsdiscover and develop novel drugs in the therapeutic area of cancer, rheumatoid arthritis and liver related diseases.

Posts Mentioning This Company

How Big Pharma Adopts AI To Boost Drug Discovery - Oct. 8, 2018
Biopharma Insights